PIN A1
Alternative Names: PIN-A1Latest Information Update: 06 Jan 2023
At a glance
- Originator Pin Therapeutics
- Class Antineoplastics; Peptides
- Mechanism of Action Casein kinase Ialpha inhibitors; Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 13 Dec 2022 PIN A1 is available for licensing as of 08 Dec 2022. https://www.pintherapeutics.com/eng/company/collaborator.html
- 26 Oct 2022 Preclinical trials in Acute myeloid leukaemia in South Korea (Intraperitoneal) before October 2022
- 26 Oct 2022 Pharmacodynamics data from preclinical studies in Acute myeloid leukemia presented at 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2022)